MarketCap
Facebook
X
Telegram
Bristol-Myers Squibb Company Income Statement 2025-2006 | BMY
Brief overview of income trends at Bristol-Myers Squibb Company
The comparison covers a five-year financial horizon. Revenue reported by Bristol-Myers Squibb Company was 42.5 billion dollars at the beginning of the period and 48.2 billion dollars at the end. The five-year change reached +13.3%, while CAGR stood at 2.5%. The business did not achieve meaningful top-line expansion.
The five-year change in gross profit reached +11.4%: from $30.7 billion to $34.3 billion. The relationship between sales and direct costs deteriorated. The gross margin was 72.3% at the start and 71.1% at the end. The gross margin stayed within a similar range.
The five-year EBITDA result moved by −61.4%: from 10.4 billion dollars to 4 billion dollars. EBITDA lagged revenue, showing weaker operating momentum. Comparing the endpoints gives EBITDA margins of 24.4% and 8.3%. The margin contraction indicates weaker operating efficiency.
Net income moved from −$9 billion at the start to $7.1 billion at the end. The trajectory reversed from a loss to positive earnings.
Market capitalization changed from 133 billion dollars to 122 billion dollars (−8%). The valuation did not keep pace with the reported progress.
Overall conclusion
Signs of deterioration dominate the five-year picture. The positive side is supported by net-income growth. The overall view is constrained by weak sales momentum, pressure from direct costs and pressure on operating profitability. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement Bristol-Myers Squibb Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
122 B | 114 B | 100 B | 154 B | 151 B | 133 B | 144 B | 79.8 B | 105 B | 81.4 B | 104 B | 99.9 B | 83 B | 61.2 B | 54.8 B | 39.4 B | 39.7 B | - | - | - |
Shares |
2.03 B | 2.03 B | 2.07 B | 2.13 B | 2.22 B | 2.26 B | 2.25 B | 1.63 B | 1.64 B | 1.67 B | 1.67 B | 1.66 B | 1.64 B | 1.67 B | 1.7 B | 1.71 B | 1.97 B | - | - | - |
Historical Prices |
60.2 | 56.2 | 48.5 | 72.5 | 68.1 | 58.9 | 55.1 | 46.6 | 58.1 | 48.4 | 51.7 | 49.6 | 42.6 | 28.3 | 23.7 | 23 | 20.1 | 22 | 30.5 | 25.1 |
Net Income |
7.05 B | -8.95 B | 8.02 B | 6.33 B | 6.99 B | -9.02 B | 3.44 B | 4.92 B | 1.01 B | 4.46 B | 1.56 B | 2 B | 2.56 B | 1.96 B | 3.71 B | 3.1 B | 10.6 B | 5.25 B | 2.16 B | - |
Revenue |
48.2 B | 48.3 B | 45 B | 46.2 B | 46.4 B | 42.5 B | 26.1 B | 22.6 B | 20.8 B | 19.4 B | 16.6 B | 15.9 B | 16.4 B | 17.6 B | 21.2 B | - | - | - | - | - |
Cost of Revenue |
13.9 B | 14 B | 10.7 B | 10.1 B | 9.94 B | 11.8 B | 8.08 B | 6.47 B | 6.01 B | 4.97 B | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | 18.1 B | 16 B | 14.7 B | 14.5 B | 12.7 B | 11.9 B | 11.8 B | 13 B | 15.6 B | 3.7 B | 3.6 B | - | - | - |
Interest Expense |
-674 M | -893 M | 1.17 B | 1.23 B | 1.33 B | 1.42 B | 656 M | 183 M | 196 M | 167 M | 184 M | 203 M | 199 M | 182 M | 145 M | 145 M | 184 M | 310 M | -77 M | - |
EBITDA |
4.01 B | 9.6 B | 9.76 B | 10.3 B | 10.7 B | 10.4 B | 7.05 B | 5.76 B | 4.24 B | 4.92 B | 2.11 B | 2.18 B | 3.69 B | 4.61 B | 7.45 B | 607 M | 469 M | 562 M | 542 M | - |
Operating Expenses |
- | - | - | - | - | - | 12.2 B | 10.9 B | 11.3 B | 9.94 B | 10.9 B | 10.2 B | 8.84 B | 9.08 B | 9 B | - | - | - | - | - |
General and Administrative Expenses |
7.27 B | 8.41 B | 7.77 B | 7.81 B | 7.69 B | 7.66 B | - | - | 162 M | 91 M | 160 M | 877 M | 165 M | 158 M | 4.2 B | 3.69 B | 3.95 B | 4.14 B | 3.94 B | - |
All numbers in USD currency
Quarterly Income Statement Bristol-Myers Squibb Company
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q3 | 2009-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
2.04 B | 2.04 B | 2.04 B | 2.04 B | 2.03 B | 2.03 B | 2.03 B | 2.02 B | 2.06 B | 2.09 B | 2.1 B | - | 2.13 B | 2.13 B | 2.15 B | - | 2.22 B | 2.23 B | 2.24 B | - | 2.26 B | 2.26 B | 2.26 B | - | 1.63 B | 1.64 B | 1.63 B | - | 1.63 B | 1.63 B | 1.63 B | - | 1.64 B | 1.64 B | 1.66 B | - | 1.67 B | 1.67 B | 1.67 B | - | 1.67 B | 1.67 B | 1.66 B | - | 1.66 B | 1.66 B | 1.65 B | - | 1.65 B | 1.64 B | 1.64 B | - | 1.67 B | 1.68 B | 1.69 B | - | 1.7 B | 1.71 B | 1.7 B | - | - | - | - | - |
Net Income |
3.32 B | 2.68 B | 2.2 B | 1.31 B | 2.46 B | 1.21 B | 1.68 B | -11.9 B | 1.93 B | 2.07 B | 2.26 B | - | 1.61 B | 1.42 B | 1.28 B | - | 1.55 B | 1.06 B | 2.02 B | -10 B | 1.87 B | -85 M | -775 M | -1.06 B | 1.35 B | 1.43 B | 1.71 B | 1.16 B | 1.9 B | 373 M | 1.49 B | -2.33 B | 845 M | 916 M | 1.57 B | 894 M | 1.2 B | 1.17 B | 1.2 B | -197 M | 706 M | -130 M | 1.19 B | 13 M | 721 M | 333 M | 937 M | 726 M | 692 M | 536 M | 609 M | 925 M | -711 M | 645 M | 1.1 B | 852 M | 969 M | 902 M | 986 M | 949 M | 927 M | 743 M | 966 M | 983 M |
Revenue |
13 B | 11.5 B | 12.2 B | 12.3 B | 11.2 B | 11.9 B | 12.2 B | 11.9 B | 11 B | 11.2 B | 11.3 B | - | 11.2 B | 11.9 B | 11.6 B | - | 11.6 B | 11.7 B | 11.1 B | 11.1 B | 10.5 B | 10.1 B | 10.8 B | 7.94 B | 6.01 B | 6.27 B | 5.92 B | 5.97 B | 5.69 B | 5.7 B | 5.19 B | 5.45 B | 5.25 B | 5.14 B | 4.93 B | 5.24 B | 4.92 B | 4.87 B | 4.39 B | 4.29 B | 4.07 B | 4.16 B | 4.04 B | 4.26 B | 3.92 B | 3.89 B | 3.81 B | 4.44 B | 4.06 B | 4.05 B | 3.83 B | 4.19 B | 3.74 B | 4.44 B | 5.25 B | 5.45 B | 5.34 B | 5.43 B | 5.01 B | - | - | - | - | - |
Cost of Revenue |
3.73 B | 3.42 B | 3.44 B | 3.37 B | 3.03 B | 2.96 B | 3.27 B | 2.93 B | 2.51 B | 2.88 B | 2.57 B | - | 2.35 B | 2.72 B | 2.47 B | - | 2.29 B | 2.45 B | 2.84 B | - | 2.5 B | 2.7 B | 3.66 B | - | 1.79 B | 1.97 B | 1.82 B | - | 1.65 B | 1.62 B | 1.58 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.16 B | 8.04 B | 7.43 B | 7.12 B | 5.45 B | 4.22 B | 4.3 B | 4.1 B | 4.3 B | 4.06 B | 4.1 B | 3.63 B | 3.77 B | 3.68 B | 3.58 B | 3.66 B | 3.86 B | 3.62 B | 3.66 B | 3.34 B | 3.34 B | 2.97 B | 3.15 B | 3.19 B | 3.29 B | 2.91 B | 2.9 B | 2.84 B | 3.17 B | 2.89 B | 2.94 B | 2.77 B | 3.12 B | 2.75 B | 3.2 B | 3.95 B | 4.09 B | 3.94 B | 3.95 B | 3.67 B | - | - | - | - | - |
Operating Income |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.4 B | - | - | - | 1.29 B | - | - | - | - | - |
Interest Expense |
61 M | -32 M | 108 M | -494 M | -339 M | -234 M | -273 M | -81 M | 258 M | 116 M | 288 M | - | 299 M | 313 M | 326 M | - | 328 M | 330 M | 353 M | - | 346 M | 357 M | 362 M | - | 209 M | 123 M | 45 M | - | 44 M | 45 M | 46 M | - | 48 M | 52 M | 45 M | - | 42 M | 42 M | 43 M | - | 41 M | 49 M | 51 M | - | 50 M | 46 M | 54 M | - | 46 M | 50 M | 50 M | - | 48 M | 41 M | 42 M | - | 40 M | 32 M | 31 M | 38 M | 32 M | -113 M | 30 M | 22 M |
EBITDA |
1.19 B | 594 M | 3.03 B | - | - | - | - | - | - | - | - | - | 148 M | 141 M | 2.58 B | - | 8.11 B | 143 M | 2.67 B | - | 7.69 B | 5.04 B | 2.48 B | - | 510 M | 339 M | 170 M | - | 465 M | 300 M | 143 M | - | 592 M | 404 M | 193 M | - | 260 M | 155 M | 65 M | - | 300 M | 195 M | 104 M | - | 364 M | 252 M | 137 M | - | 582 M | 402 M | 213 M | - | 482 M | 287 M | 1.54 B | - | 482 M | 228 M | 1.4 B | 348 M | 246 M | 122 M | 348 M | 231 M |
General and Administrative Expenses |
1.83 B | 1.62 B | 1.79 B | 1.71 B | 1.58 B | 1.98 B | 1.93 B | 2.37 B | 2 B | 1.93 B | 1.76 B | - | 1.93 B | 1.79 B | 1.83 B | - | 1.79 B | 1.88 B | 1.67 B | - | 1.71 B | 1.63 B | 1.61 B | - | 1.06 B | 1.08 B | 1.01 B | - | 1.1 B | 1.13 B | 980 M | - | 1.16 B | 1.19 B | 1.08 B | - | 1.14 B | 1.24 B | 1.07 B | - | 1.18 B | 1.14 B | 1.03 B | - | 1.03 B | 951 M | 957 M | - | 980 M | 1.04 B | 994 M | - | 1.07 B | 1 B | 1 B | - | 1.02 B | 1.04 B | 928 M | 892 M | 894 M | 900 M | 1.12 B | 1.08 B |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Bristol-Myers Squibb Company (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Canada
China
France
Germany
Israel
Britain
Russia
Belgium
Cayman-islands